Skip to main content

Anson Funds Management LP

Position in SLS — SELLAS Life Sciences Group, Inc.

CIK 1491072 DALLAS, TX

Position in SLS

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$66,420,000
+$56,706,970 QoQ
Shares Held
4,500,000
-25.4% QoQ
Ownership
2.23%
of shares outstanding
% of Portfolio
7.67%
of 13F equity value
Holder Rank
#5
of 189 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SLS Over Time

Shares Held

Position Value (USD)

Derivatives in SLS

reported options exposure · as of Jun 30, 2026
CallValue
$11,808,000
CallShares
800,000
PutValue
$27,245,484
PutShares
1,845,900

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Anson Funds Management LP holds $75,470,163 across 8 Biotechnology names. SLS ranks #1 (88.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 SLS
SELLAS Life Sciences Group, Inc.
This page
4,500,000 $66,420,000

All Filings in SLS

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $66,420,000 4,500,000
2026-06-30 $27,245,484 1,845,900
2026-06-30 $11,808,000 800,000
2025-09-30 $9,713,030 6,032,938
2025-06-30 $602,250 275,000
2025-03-31 $8,185,422 7,579,095
2024-12-31 $1,239,956 1,192,266
2024-09-30 $992,293 793,835
2024-03-31 $4,880,691 4,832,368